Neurix SA is a Swiss biotech company that offers human in vitro neural tissues for accelerating drug development and testing neurotoxicity of drugs as well as chemicals. Neurix’s technology provides the unique opportunity for the pharmaceutical industry to directly test newly discovered compounds on human material during early-phase drug development. Furthermore, chemical companies can use the in vitro tissues and in-house services to test for neurotoxicity of chemicals, as an alternative tool to animals to comply with the most stringent environmental regulations.
The role of NEURIX within the NEURINOX consortium consists in developing human in vitro models of neuroinflammation as drug-efficacy screening platforms. These models, generated from induced pluripotent stem cells (iPSCs), will be used as alternative human platforms to screen compounds (e.g. NOX inhibitors) provided by NEURINOX partners; the first model will be in 2D while the second one will present a 3D brain-like structure. Thus, NEURINOX compounds will get unique additional value thanks to direct indication of their neurotoxicity and efficacy against neuroinflammation on human tissue at an early stage in their development process.
Role in the Project
Mathurin Baquié, PhD and Managing Director at Neurix, brings expertise in biochemistry and toxicology. Dr Baquié was trained at renowned North American as well as European institutions.
Christophe Delgado, Cell Lab Manager at Neurix, is expert in stem cell culture, neural differentiation and cell engineering.